李成林

个人简历

李成林，男，博士，教授，博士研究生导师，江苏省“六大人才高峰”高层次人才、江苏省“333工程”第三层次培养对象。2012年毕业于中国药科大学药理学专业获理学博士。研究方向为肿瘤发生发展机制及干预研究、肿瘤早期诊断及标志物研究。主持各级各类课题9项，其中国家级课题2项、省部级课题4项。相关工作以第一或通讯作者发表论文31篇，其中在Cancer Letters、Acta Pharmacologica Sinica、Small、Analytical Chemistry等杂志发表SCI论文26篇。获国家发明专利3项，申请发明专利1项。获江苏省教学成果奖二等奖、2016-2017年度徐州市自然科学优秀学术论文奖二等奖、2020-2021年度徐州市自然科学优秀学术论文奖二等奖、贵州医学科技奖一等奖。

承担科研课题

1.     国家自然科学基金委员会，面上项目，82173851，FOXO3/YAP信号轴调控肝细胞癌代谢重编程及新化合物6H2L的干预研究，2022-01至2025-12，55万元，在研，主持

2.     江苏省科技厅，江苏省自然科学基金面上项目，BK20211350，新化合物6H2L基于FOXO3/YAP信号轴的肝细胞癌代谢重编程干预研究，2021-07至2024-06，10万元，在研，主持

3.     徐州市科学技术局，徐州市推动科技创新项目，KC20066，新化合物LFG-500抗肿瘤代谢重编程研究，2020-08至2022-07，6万元，已结题，主持

4.     中共江苏省委组织部、江苏省人力资源和社会保障厅、江苏省财政厅，江苏省“六大人才高峰”高层次人才，2017-SWYY-075，2018-01至2021-12，8万元，已结题，主持

5.     国家自然科学基金委员会，青年项目，81402969，基于ILK/Hippo通路的黄酮类新化合物LFG-500抗肿瘤上皮间质转化研究，2015-01至2017-12，23万元，已结题，主持

6.     江苏省科技厅，江苏省自然科学基金青年项目，BK20130220，黄酮类新化合物LFG-500基于炎症微环境诱导上皮间质转化的抗肿瘤转移研究，2013-07至2016-06，20万元，已结题，主持

7.     中国博士后科学基金会，中国博士后科学基金面上资助，2013M541733，LFG-500抗炎症微环境诱导的肿瘤上皮间质转化研究，2013-09至2016-07，5万元，已结题，主持

8.     江苏省人力资源和社会保障厅，江苏省博士后科研资助计划，1301015B，黄酮类新化合物LFG-500抗炎症微环境诱导的肿瘤上皮间质转化（EMT）研究，2013-09至2016-07，5万元，已结题，主持

9.     江苏省教育厅，江苏省高校自然科学基金面上项目，13KJB350007，新化合物LFG-500抗炎症微环境诱导的肿瘤上皮间质转化研究，2013-10至2015-12，3.2万元，已结题，主持

近五年代表性论文、专著

1.      Xiao Yang, Zhou Zhiyi, Zuo Yifan, Wu Xueyuan, Liu Yuping, Li Yichen, Gao Yuetong, Zhang Xiashu, Wang Yu, Hu Lili, Li Chenglin*, Layer-by-layer fabrication of alginate/polyethyleneimine multilayer on magnetic interface with enhanced efficiency in immuno-capturing circulating tumor cells, Analytica Chimica Acta, 2024, 1312:342778.

2.      Xu Hao, Zuo Yingchun, Gao Shuai, Liu Yuping, Liu Tingting, He Shiyu, Wang Mengjiao, Hu Lili, Li Chenglin*, Yu Yanyan*, Circulating Tumor Cell Phenotype Detection and Epithelial-Mesenchymal Transition Tracking Based on Dual Biomarker Co-Recognition in an Integrated PDMS Chip, Small, 2024, 20(36): e2310360.

3.      Zuo Yifan, Lu Wenwen, Xia Yi, Meng Jiali, Zhou Yi, Xiao Yang, Zhu Liang, Liu Duanjiao, Yang Shenhao, Sun Yuqing, Li Chenglin*, Yu Yanyan*, Glucometer Readout for Portable Detection of Heterogeneous Circulating Tumor Cells in Lung Cancer Captured on a Dual Aptamer Functionalized Wrinkled Cellulose Hydrogel Interface, ACS Sensors, 2023, 8(1): 187-196.

4.      Zuo Yifan, Xia Yi, Lu Wenwen, Li Yue, Xiao Yang, Gao Shuai, Zhou Zhiyi, Xu Hao, Feng Xingqing, Li Chenglin*, Yu Yanyan*, A multifunctional black phosphorus nanosheet-based immunomagnetic bio-interface for heterogeneous circulating tumor cell capture and simultaneous self-identification in gastric cancer patients, Nanoscale, 2023, 15(8): 3872-3883.

5.      Wang Fan^#, Liao Rong^#, Wang Xin, Xiong Guixiang, Zhang Beibei, Li Juan, Wu Dengpan, Chen Yan, Zhou Xueyan, Gu Xiaoke, Qi Qi, Li Chenglin*, N-3, a novel synthetic derivative of bifendate, inhibits metastasis of triple-negative breast cancer via decreasing p38-regulated FOXC1 protein stability, Biochemical Pharmacology, 2023, 215:115729.

6.      Li Chenglin^#; Li Rui^#; Wu Xueyuan^#; Zuo Yifan; Xiong Guixiang; Huang Meng; Sun Yuqing; Liao Rong; Xiao Yang; Hu Lili; Gao Chao; Yu Yanyan*; Capture of heterogeneous circulating tumor cells in colorectal cancer patients on an immunomagnetic and anti-nonspecific adsorption platform, Analytical Chemistry, 2022, 94(44): 15240-15249.

7.      Li Chenglin^#; Yang Shenhao^#; Li Rui^#; Gong Shuyuan; Huang Meng; Sun Yuqing; Xiong Guixiang; Wu Dengpan; Ji Miaojin; Chen Yan; Gao Chao; Yu Yanyan*; Dual-aptamer-targeted immunomagnetic nanoparticles to accurately explore the correlations between circulating tumor cells and gastric cancer, ACS Applied Materials & Interfaces, 2022, 14(6): 7646-7658.

8.      Li Chenglin^#; Feng Xingqing^#, Yang Shenhao, Xu Hao, Yin Xiaoxing*, Yu Yanyan*; Capture, detection, and simultaneous identification of rare circulating tumor cells based on a rhodamine 6G-loaded metal-organic framework, ACS Applied Materials & Interfaces, 2021, 13(44), 52406-52416.

9.      Li Chenglin^#; Li Juan^#; Gong Shuyuan; Huang Meng; Li Rui; Xiong Guixiang; Wang Fan; Zou Qiuming; Qi Qi*; Yin Xiaoxing*; Targeting the ILK/YAP axis by LFG-500 blocks epithelial-mesenchymal transition and metastasis, Acta Pharmacologica Sinica, 2021, 42(11):1847-1859.

10.  Yu Lirong^#; Wang Fan^#; Tai Mengying; Li Juan; Gong Shuyuan; Zhou Zhengwei; Yin Xiaoxing; Gu Xiaoke; Li Chenglin*; 6H2L, a novel synthetic derivative of bifendate, induces apoptosis in hepatoma cells via mitochondrial and MAPK pathway, European Journal of Pharmacology, 2020, 882:173299. 

11.  Han Jing; Meng Tingting; Chen Xinyu; Han Yue; Fu Junjie*; Zhou Feng; Fei Yingying; Li Chenglin*; The chronic administration of two novel long-acting Xenopus glucagon-like peptide-1 analogues xGLP159 and xGLP296 potently improved systemic metabolism and glycemic control in rodent models, The FASEB Journal, 2019, 33(6): 7113-7125.

12.  Gao Jian*; Zhang Yiran; Chen Han; Chen Qingqing; Feng Dingding; Zhang Ling; Li Chenglin*; Computational insights into the interaction mechanism of transcription cofactor vestigial-like protein 4 (VGLL4) binding to TEA domain transcription factor 4 (TEAD4) by molecular dynamics simulation and molecular mechanics generalized Born/surface area (MM/GBSA) calculation, Journal of Biomolecular Structure & Dynamics, 2019, 37(10): 2538-2545.